semaglutide and cagrilintide semaglutide/cagrilintide blend (5 mg) + (5 mg) semaglutide cagrilintide Cagrilintide–semaglutide (CagriSema) versus – Semaglutide + Cagrilintide Blend |

Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA

this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults

:

For cells grown at 10 MPa (Figure 3A), 20 MPa (Figure 3C) and 30 MPa (Figure 3E), extracellular material or cellular debris, and clumped cells were observed

Hard to see how Part D plans cover these drugs and indications without substantial additional spending

Clinical data shows an average regain of 5070% of lost weight within 12 months after discontinuation, though individual results vary significantly